HR 2716

Reducing Fraudulent and Imitation Drugs Act of 2007

Congress: 110 (2007–2009, Ended)
Chamber: House
Policy Area: Health
Introduced: Jun 14, 2007
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Jun 14, 2007)
Official Text: https://www.congress.gov/bill/110th-congress/house-bill/2716

Sponsor

Name: Rep. Burton, Dan [R-IN-5]
Party: Republican • **State:** IN • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Herseth Sandlin, Stephanie [D-SD-At Large]	D · SD		Jul 17, 2007

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 14, 2007

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jun 14, 2007)

Reducing Fraudulent and Imitation Drugs Act of 2007 - Directs the Secretary of Health and Human Services to require prescription drug packaging to incorporate: (1) radio frequency tagging technology or similar trace and track technologies; (2) tamper-indicating technologies; and (3) blister security packaging when possible.

Directs the Secretary to: (1) require that such technologies be used exclusively to authenticate the pedigree of prescription drugs; and (2) prohibit such technologies from containing or transmitting any identifying information of a health care practitioner or consumer, or any advertisement or information about indications or off-label uses.

Requires the Secretary to encourage prescription drug manufacturers and distributors to incorporate: (1) overt optically variable counterfeit-resistant technologies into packaging; and (2) required prescription drug packaging technologies into multiple elements of the physical packaging of the drugs. Requires prescription drug shipments to include a label on the shipping container that incorporates packaging technologies.

Deems a prescription drug to be misbranded if the packaging or labeling of the drug is in violation of a requirement or prohibition of this Act.

Requires the Secretary to publish the National Specified List of Susceptible Prescription Drugs, consisting of not less than 30 of the most frequently counterfeited prescription drugs in the United States.

Actions Timeline

- **Jun 14, 2007:** Introduced in House
- **Jun 14, 2007:** Referred to the House Committee on Energy and Commerce.
- **Jun 14, 2007:** Referred to the Subcommittee on Health.